Ignite Creation Date:
2024-05-05 @ 12:09 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00251589
Status:
TERMINATED
Last Update Posted:
2015-03-06
First Post:
2005-11-07
Brief Title:
A Phase III Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With RelapsedRefractory Non-Small-Cell Lung Cancer 0683-025
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Phase III Clinical Trial of Oral Vorinostat MK0683 in Combination With Erlotinib in Patients With RelapsedRefractory Non-Small-Cell Lung Cancer
Status:
TERMINATED
Status Verified Date:
2015-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
This trial is being closed based on lack of substantive efficacy slow accrual and overall tolerance in patients treated to date
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The reason for this study will be to find the safest maximum tolerated dose of oral vorinostat in combination with erlotinib Tarceva TM that can be given to patients with lung cancer who have relapsed or failed other therapy for the disease Once the safest maximum tolerated dose of vorinostat is determined patients enrolled in the clinical trial will continue vorinostat and erlotinib for up to 8 months Safety and effectiveness will also be evaluated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005_080 | OTHER | Merck | None |
| MK0683-025 | OTHER | None | None |